Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers.
about
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and LipidomicsSnake venom PLA2s inhibitors isolated from Brazilian plants: synthetic and natural moleculesThe role of T and B cells in human atherosclerosis and atherothrombosisPhospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizationsType II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization studyAdmission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.Phospholipase A(2) enzymes in metabolic and cardiovascular diseases.Lp-PLA2 Inhibitors for the Reduction of Cardiovascular EventsFunctional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2.Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.Periodontal microbiota and phospholipases: the Oral Infections and Vascular Disease Epidemiology Study (INVEST).Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and AtherosclerosisLipoprotein-associated phospholipase A(2) mass and activity and risk of cardiovascular disease in a population with high prevalences of obesity and diabetes: the Strong Heart StudyLDL from obese patients with the metabolic syndrome show increased lipid peroxidation and activate platelets.Transcriptome Analysis Reveals Regulation of Gene Expression for Lipid Catabolism in Young Broilers by Butyrate Glycerides.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Phospholipids in milk fat: composition, biological and technological significance, and analytical strategies.Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation.Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA₂ in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome.Statins as first-line therapy for acute coronary syndrome?Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.Emerging families of biomarkers for coronary artery disease: inflammatory mediatorsMolecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A2 and secretory phospholipase A2 in patients with newly diagnosed type 2 diabetesMercury Exposure and Heart Diseases.Lipoprotein-associated phospholipase A₂ mass level is increased in elderly subjects with type 2 diabetes mellitus.Role of phospholipid oxidation products in atherosclerosis.Molecular biology of atherosclerosis.Novel metabolic biomarkers of cardiovascular disease.New and emerging biomarkers in cardiovascular disease.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Immune-mediated mechanisms of atherosclerosis and implications for the clinic.Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor.
P2860
Q26774903-F23869AC-8194-4593-B601-72BC9D614AB5Q26862510-40B2562B-17D0-4865-B263-DAB4A8228EEEQ27000791-98E9A37F-3B75-4BD4-806B-C8C9B9CB4AA7Q28286551-75CFEC35-B8B7-4E84-A575-9A409BAB23F7Q28479244-F8D3EC93-3F5A-460A-AA9E-7F4B9BA75DD4Q33553503-6BE63C9C-9B56-48BA-9F42-F7F1D43C5FDEQ33773427-05BCC948-A02B-443F-A7EF-A777562ECD2FQ33936097-80D971CD-F46C-4459-9E8C-BDA6BECC987EQ34373883-EE29522D-B5C1-4330-866C-46DEFD3596EFQ35212898-046C18E8-72AC-449E-833F-26C210ACACD7Q35590666-BAC8179C-BE4D-4E78-8907-B310EF36BBC9Q35592510-E83D7D80-0B6E-473F-96FB-7393435FE852Q35616605-49086B24-EC18-4179-A205-E54EA9192E0FQ35627513-A639E89F-81C2-40CD-8925-993BB7D2C5B3Q35748267-F532F148-ADC0-4DB5-8198-C904D01162F9Q35764402-1377BF31-F362-43E0-9BB8-099E9E0725F1Q35841269-B6C8B988-E585-45C6-A872-62777F5B0D3DQ36008276-C1023113-5CAC-4FCE-96C4-8D2DEC1C7BADQ36100254-7C2C3C36-586F-4581-ACDC-B5D6D69EE246Q36145180-B1FA2978-6214-4166-BCD7-FB2B87CAD67AQ36656006-F14C3820-1652-4739-A3B0-505A58D9AF43Q36681188-DF0489F2-E76D-4B72-8715-D8921A804523Q36686099-25D6CA7C-97DD-4ECF-A975-BC53C45E820BQ36716991-55E60601-DF83-49A3-BCB8-0D12161180D8Q36768488-95D9CF9C-6C10-4B44-8AE7-4667F1CE03B6Q37019583-A47CD046-39AB-4F7C-B4EC-A9F0A60D734DQ37076194-84857076-9686-4D21-A3E4-7941AD6BE9A0Q37115819-6079826B-8F06-4368-AE63-517E1FD15F6AQ37254899-2107B4DD-8826-4CAC-B484-EC9EC2EBA24EQ37303915-39352B1E-6B63-4EA2-B074-41E66F9C5E93Q37431606-05ECCA0B-897E-4378-83EA-430B3CAED2ACQ37628817-9F956E9E-51C8-4904-9815-3FBA2C8EAEF7Q37730748-544D3459-CA18-4BDC-AED4-EAE3685AD157Q38039282-EB6E8366-E66E-451B-B011-CDDC6396686CQ38125279-DB68D8AB-5BA7-4E1D-9B0D-CB27384CE7FAQ38245327-335CF0D8-F006-48AA-8762-63D3EA589596Q38586900-06829820-3921-4170-B48F-71CB57DABCCAQ38786058-24614DF7-2FEC-4A86-A29B-2F23606196A0Q38851472-63FBD172-C151-4C55-8FDD-6E84D96BFBD6Q39011074-0041B41C-D10E-4BF1-B42A-16FBB639BEF2
P2860
Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@ast
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@en
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@nl
type
label
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@ast
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@en
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@nl
prefLabel
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@ast
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@en
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@nl
P921
P1433
P1476
Lipoprotein-associated and sec ...... ical effectors and biomarkers.
@en
P2093
Gérard Lambeau
P304
P356
10.1161/CIRCULATIONAHA.110.936393
P407
P577
2010-11-01T00:00:00Z